Lyell Immunopharma (LYEL) EV/EBITDA: History & Chart

Lyell Immunopharma, Inc.(LYEL)

Biotechnology · South San Francisco, CA

$9.03-0.04 (-0.50%)

Delayed quote: Oct 6, 2026, 12:50 PM EDT

About Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

South San Francisco, CA

161 employees

www.lyell.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Lynn Seely

View full financials

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Lyell Immunopharma, Inc. (LYEL)	$221.15M	N/A	N/A	N/A	N/A
Keros Therapeutics, Inc. (KROS)vs ›	$223.58M	N/A	1.40x	1.40x	1.40x
Profound Medical Corp. (PROF)vs ›	$225.47M	N/A	N/A	N/A	N/A
Anbio Biotechnology Class A Ordinary Shares (NNNN)vs ›	$215.07M	N/A	N/A	N/A	N/A
Niagen Bioscience Inc (NAGE)vs ›	$214.17M	14.35x	22.76x	55.61x	55.61x
Prelude Therapeutics Incorporated (PRLD)vs ›	$213.50M	N/A	N/A	N/A	N/A
Alector, Inc. (ALEC)vs ›	$213.17M	N/A	16.55x	16.55x	16.55x
Biodesix, Inc. (BDSX)vs ›	$231.01M	N/A	N/A	N/A	N/A
Compugen Ltd. (CGEN)vs ›	$210.85M	N/A	6.24x	9.83x	9.83x
BioAge Labs Inc. (BIOA)vs ›	$232.49M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EV/EBITDA RATIO

TTM

Lyell Immunopharma, Inc. (LYEL)

$221.15M

N/A

Keros Therapeutics, Inc. (KROS)vs ›

$223.58M

N/A

1.40x

Profound Medical Corp. (PROF)vs ›